Does FAD-dependent polyamine oxidase contribute to the metabolism of milacemide?
Milacemide, a secondary amine derivative, was previously demonstrated to be a substrate of MAO-B and to be insensitive to the action of copper-dependent amine oxidases. In the present study, it was investigated whether the FAD-dependent secondary amine metabolizing enzyme polyamine oxidase (PAO), could participate in the metabolism of milacemide. For this purpose, the urinary metabolic pattern of oral 14C-milacemide was determined in rats with and without pretreatment with the irreversible PAO inhibitor MDL 72527 and, for comparison, after inhibition of MAO-B by 1-deprenyl.
While 1-deprenyl was shown to significantly decrease the urinary excretion of glycinamide and of an unknown metabolite (UK1, pretreatment with MDL 72527 did not modify the elimination of milacemide as glycinamide but produced a decrease in UK1 equal to that induced by 1-deprenyl. The percent of the dose of milacemide eliminated as unchanged drug was slightly but significantly increased after PAO inhibition, though considerably less than after 1-deprenyl. These data suggest that milacemide might be a substrate of PAO. If confirmed, this result would constitute the first example of the involvement of the FAD-dependent PAO in drug metabolism.
KeywordsMonoamine Oxidase Secondary Amine Amine Oxidase Polyamine Oxidase Unknown Metabolite
Unable to display preview. Download preview PDF.
- Seiler N (1987) Inhibition of enzymes oxidizing polyamines. In: McCann PP, Pegg AE, Sjoerdsma A (eds) Inhibition of polyamine metabolism. Academic Press, Orlando, pp 49–77.Google Scholar
- Strolin Benedetti M (1989) Oxidative drug metabolism not cytochrom P-450 dependent. Actual Chim Thér 16:337–356.Google Scholar
- Strolin Benedetti M, Sontag N, Boucher T, Kan JP (1981) Aliphatic amines as MAO substrates in the rat: the effect of selective inhibitors on the deamination of n-pentylamine. In: Usdin E, Weiner N, Youdim MBH (eds) Function and regulation of monoamine enzymes. Macmillan, London, pp 527–538.Google Scholar
- Strolin Benedetti M, Dostert P, Guffroy C, Tipton KF (1983) Partial or total protection from long-acting monoamine oxidase inhibitors by new short-acting MAOIs of type A MD 780515 and type B MD 780236. Mod Probl Pharmacopsychiatry 19:82–104.Google Scholar